Soybean soapstock(SS) is one of the main solid wastes produced in the refinery of edible oil processing. In this study, the co-pyrolysis of SS with iron slag(IS) and aluminum scrap(AS) was carried out in a tubular fur...Soybean soapstock(SS) is one of the main solid wastes produced in the refinery of edible oil processing. In this study, the co-pyrolysis of SS with iron slag(IS) and aluminum scrap(AS) was carried out in a tubular furnace. The gas, liquid and solid products were characterized and the char yield decreased with increasing IS/AS ratio. IS and AS can improve the gas yield, and when the ratio of SS/IS was 1:0.25, the total pyrolysis gas and hydrogen contents were significantly increased. The content of oxygen compounds in pyrolysis oil decreased during co-pyrolysis, while AS promoted the content of polycyclic aromatic hydrocarbons in pyrolysis oil. The co-pyrolysis reaction can be divided into four stages, the mass loss rate reaches the maximum at the third stage(390–575 ℃). The molar ratio of H/C was lower for pyrolysis,indicating good stability of pyrolysis char owing to the high degree of carbonization and aromaticity.The possible co-pyrolysis reaction mechanism was explored.展开更多
No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functi...No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functional disability in survivors require clinical evaluation.We performed a parallel assigned controlled,non-randomized,phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells(UC-MSCs)infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.The study enrolled 18 hospitalized patients with COVID-19(n=9 for each group).The treatment group received three cycles of intravenous infusion of UC-MSCs(3×107 cells per infusion)on days 0,3,and 6.Both groups received standard COVID-treatment regimens.Adverse events,duration of clinical symptoms,laboratory parameters,length of hospitalization,serial chest computed tomography(CT)images,the PaO2/FiO2 ratio,dynamics of cytokines,and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed.No serious UC-MSCs infusion-associated adverse events were observed.Two patients receiving UC-MSCs developed transient facial flushing and fever,and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion.Mechanical ventilation was required in one patient in the treatment group compared with four in the control group.All patients recovered and were discharged.Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated.Phase 2/3 randomized,controlled,double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.展开更多
基金supported by China-Central and Eastern Europe Universities Joint Education Project(2021128).
文摘Soybean soapstock(SS) is one of the main solid wastes produced in the refinery of edible oil processing. In this study, the co-pyrolysis of SS with iron slag(IS) and aluminum scrap(AS) was carried out in a tubular furnace. The gas, liquid and solid products were characterized and the char yield decreased with increasing IS/AS ratio. IS and AS can improve the gas yield, and when the ratio of SS/IS was 1:0.25, the total pyrolysis gas and hydrogen contents were significantly increased. The content of oxygen compounds in pyrolysis oil decreased during co-pyrolysis, while AS promoted the content of polycyclic aromatic hydrocarbons in pyrolysis oil. The co-pyrolysis reaction can be divided into four stages, the mass loss rate reaches the maximum at the third stage(390–575 ℃). The molar ratio of H/C was lower for pyrolysis,indicating good stability of pyrolysis char owing to the high degree of carbonization and aromaticity.The possible co-pyrolysis reaction mechanism was explored.
基金supported by The National Key R&D Program of China(2020YFC0841900,2020YFC0844000)The Innovation Groups of the National Natural Science Foundation of China(81721002)+2 种基金The National Science and Technology Major Project(2017YFA0105703)The Military Emergency Research Project for COVID-19(BWS20J006)The Project for Innovation of Military Medicine of China(16CXZ045).
文摘No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functional disability in survivors require clinical evaluation.We performed a parallel assigned controlled,non-randomized,phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells(UC-MSCs)infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.The study enrolled 18 hospitalized patients with COVID-19(n=9 for each group).The treatment group received three cycles of intravenous infusion of UC-MSCs(3×107 cells per infusion)on days 0,3,and 6.Both groups received standard COVID-treatment regimens.Adverse events,duration of clinical symptoms,laboratory parameters,length of hospitalization,serial chest computed tomography(CT)images,the PaO2/FiO2 ratio,dynamics of cytokines,and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed.No serious UC-MSCs infusion-associated adverse events were observed.Two patients receiving UC-MSCs developed transient facial flushing and fever,and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion.Mechanical ventilation was required in one patient in the treatment group compared with four in the control group.All patients recovered and were discharged.Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated.Phase 2/3 randomized,controlled,double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.
